New neurology medication usage low due to high costs, similar effectiveness

Future studies are needed to determine if cost is a barrier for new medications with greater efficacy.

9:53 AM

Author | Noah Fromson

pills
Jacob Dwyer, Justine Ross, Michigan Medicine

While many new medications designed to treat neurologic diseases have hit the market, utilization by patients remains low due to high costs and similar effectiveness to existing drugs, a new study funded by the American Academy of Neurology finds.

A research team led by Michigan Medicine used pharmaceutical claims data from 2001 to 2019 to analyze use of new-to-market medications and existing guideline-supported medications for patients with one of 11 neurologic conditions, including multiple sclerosis, Parkinson's disease and migraine.

Results published in Neurology, the medical journal of AAN, reveal that fewer than 20% of patients were treated with new medications approved by the FDA between 2014 and 2018, while costs of these medications were significantly higher than existing treatments. The only condition with a higher usage rate of new medications was tardive dyskinesia at 32%.

The most expensive new treatment was edaravone for ALS at an average out-of-pocket cost of $713 a month. Researchers say the out-of-pocket costs for newer medications were more unpredictable than the costs for existing drugs due to the higher general costs of the medications and differences in each patient's insurance coverage.

"While some medications have shown a small increase in use, the overall impact of these new drugs is small, likely due to the comparable efficacy to the lower priced medications that were already on the market," said senior author Brian C. Callaghan, M.D., M.S., a neurologist at University of Michigan Health and the Eva L. Feldman, MD, PhD, Professor of Neurology at U-M Medical School. "Providers might also be deterred from prescribing these drugs due to high costs or insurance barriers. We must work to ensure that treatments for neurological conditions are affordable for patients."

Medications for two rare conditions, spinal muscular atrophy and transthyretin amyloidosis, have drastically improved outcomes. Researchers, however, were not able to analyze the effect of costs on use due to a limited number of participants.

View the release from the American Academy of Neurology.

Additional authors include Evan L. Reynolds, Ph.D., Gary Gallagher, M.D., Chloe E. Hill, M.D., Mousumi Banerjee, Ph.D., all of University of Michigan, Aristotle Mante, The American Academy of Neurology, and Gregory J. Esper, M.D., M.B.A., Emory University.

Disclosure: Callaghan consults for DynaMed, receives research support from the American Academy of Neurology and performs medical legal consultations including consultations for the Vaccine Injury Compensation Program.

Paper Cited: "Costs and Utilization of New-to-Market Neurologic Medications," Neurology. DOI: 10.1212/WNL.0000000000201627


More Articles About:

Lab Notes Lou Gehrig's (ALS) Multiple Sclerosis (MS) Parkinson's Disease Medication Guidelines Drug Discovery Neurological (Brain) Conditions
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Close up of woman's mouth as cheek swab is performed, with Q tip held in a green medical gloved hand.
Health Lab

Are you at risk of a genetic disease? Guidelines for testing should be updated, experts say

Genetic counselor calls for updated guidelines on testing for diseases like Huntington's and Alzheimer's diseases.
Young boy in purple t-shirt sits smiling in the grass on a sunny day.
Health Lab

From 20 seizures a day to more time for play: How personalized epilepsy care helped young patient

Advanced genetic testing and a detailed diagnosis revealed infant’s rare epilepsy, leading to a non-conventional therapy.
David Diebold smiles as he rings the bell at the end of the HURT100.
Philanthropy News

Going the extra 100 miles

U-M Medical School student runs the HURT100 ultramarathon to raise funds for the Michigan Alzheimer's Disease Center and the Alzheimer's Association.
Cole, wearing sunglasses and a purple Calming the Storm t-shirt with a rainbow, is seated on a blanket outdoors and holding a Mott teddy bear.
Philanthropy News

A pediatric epilepsy fundraiser that changes lives

Your support of Calming the Storm advances pediatric epilepsy research and patient care programs. There are many ways you can contribute to make a difference for so many children and families.
Two people in medical scrubs are in a blurred hospital setting. In the foreground, hands are holding a digital tablet.
Health Lab

Digital alerts support timely treatment decisions of critically ill cardiac patients

Well-designed alerts for critically ill cardiac patients can change what happens at the bedside, according to new Michigan Medicine research.
Doctor performing a test
News Release

Michigan Alzheimer's Disease Research Center receives $22M to advance efforts statewide

NIH renews $22M for Michigan Alzheimer's Disease Research Center, supporting a first-of-its-kind statewide partnership and dementia research.